Dr. Peder Andersen, MD

Board Member

Chief Medical Officer

Chief Operations Officer

30+ years of international biotech and pharma leadership, advancing drug development and guiding companies to IPO.

Proven CEO record: led Biosergen AS (Invasive Fungal Infections) to IPO in Sweden (2021), CEO of Forward Pharma, leading Nasdaq IPO (2014) raising $235M.

Clinical and regulatory expertise: MD with training in surgery, anesthesiology, intensive care, and internal medicine; development experience in psoriasis, MS, lupus, Crohn’s , infectious diseases.

Industry Knowledge: senior leadership / MD roles at Forward Pharma Germany (DMF - psoriasis, MS),  Astion Pharma (Psoriasis, Lupus), Sandoz Pharma, Basel (GM-CSF, Mb Crohn, Psoriasis), and Novo Nordisk (Nasal Insulin, HGH).

Academic foundation: MD, Copenhagen University Medical School, training in surgery, anesthesiology, intensive care, internal medicine.

Shareholder and Board member,  bringing regulatory, operational, and IPO know-how.